Lv1
40 积分 2024-04-07 加入
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
2天前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
3天前
已完结
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
3天前
已完结
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
3个月前
已完结
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
3个月前
已完结
ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications
4个月前
已完结
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
6个月前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
6个月前
已完结
Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer
7个月前
已完结
皖公网安备34019202002308
